{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T13:50:05Z","timestamp":1792245005430,"version":"4.4.0"},"reference-count":170,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s11102-026-01667-9","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T14:13:55Z","timestamp":1780064035000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Osteometabolic complications in patients with secreting pituitary adenomas: Is there an impact of gender?"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-6117-0081","authenticated-orcid":false,"given":"Luigi","family":"di Filippo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Acanfora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Bolamperti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Terenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maristella","family":"Bonomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Giustina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"issue":"1","key":"1667_CR1","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s12020-011-9570-2","volume":"41","author":"G Mazziotti","year":"2012","unstructured":"Mazziotti G, Bilezikian J, Canalis E et al (2012) New understanding and treatments for osteoporosis. Endocrine 41(1):58\u201369. https:\/\/doi.org\/10.1007\/s12020-011-9570-2","journal-title":"Endocrine"},{"key":"1667_CR2","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s001980050281","volume":"11","author":"JA Kanis","year":"2000","unstructured":"Kanis JA, Gl\u00fcer CC (2000) An update on the diagnosis and assessment of osteoporosis with densitometry. Osteoporos Int 11:192\u2013202. https:\/\/doi.org\/10.1007\/s001980050281","journal-title":"Osteoporos Int"},{"key":"1667_CR3","doi-asserted-by":"publisher","unstructured":"GBD (2019) Fracture Collaborators. Global, regional, and national burden of bone fractures in 204 countries and territories, 1990\u20132019: A systematic analysis from the Global Burden of Disease Study 2019. Lancet Healthy Longev. 2021;2(9):e580-e592. https:\/\/doi.org\/10.1016\/S2666-7568(21)00172-0","DOI":"10.1016\/S2666-7568(21)00172-0"},{"issue":"4","key":"1667_CR4","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00198-008-0560-z","volume":"19","author":"JA Kanis","year":"2008","unstructured":"Kanis JA, Burlet N, Cooper C (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19(4):399\u2013428. https:\/\/doi.org\/10.1007\/s00198-008-0560-z","journal-title":"Osteoporos Int"},{"issue":"1","key":"1667_CR5","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11657-020-0706-y","volume":"15","author":"F Borgstr\u00f6m","year":"2020","unstructured":"Borgstr\u00f6m F, Karlsson L, Orts\u00e4ter G (2020) Fragility fractures in Europe: Burden, management and opportunities. Arch Osteoporos 15(1):59. https:\/\/doi.org\/10.1007\/s11657-020-0706-y","journal-title":"Arch Osteoporos"},{"issue":"1","key":"1667_CR6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s12020-022-03150-4","volume":"78","author":"L di Filippo","year":"2022","unstructured":"di Filippo L, Compagnone N, Frara S et al (2022) Vertebral fractures at hospitalization predict impaired respiratory function during follow-up of COVID-19 survivors. Endocrine 78(1):5\u201314. https:\/\/doi.org\/10.1007\/s12020-022-03150-4","journal-title":"Endocrine"},{"issue":"9","key":"1667_CR7","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1056\/NEJMra067395","volume":"357","author":"E Canalis","year":"2007","unstructured":"Canalis E, Giustina A, Bilezikian JP (2007) Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 357(9):905\u2013916. https:\/\/doi.org\/10.1056\/NEJMra067395","journal-title":"N Engl J Med"},{"issue":"6","key":"1667_CR8","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s40618-025-02544-1","volume":"48","author":"L di Filippo","year":"2025","unstructured":"di Filippo L, Doga M, Mangini F et al (2025) Morphometric vertebral fractures at hospitalization associate with Long COVID occurrence. J Endocrinol Invest 48(6):1371\u20131382. https:\/\/doi.org\/10.1007\/s40618-025-02544-1","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"1667_CR9","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s40618-017-0761-4","volume":"41","author":"C Cipriani","year":"2018","unstructured":"Cipriani C, Pepe J, Bertoldo F et al (2018) The epidemiology of osteoporosis in Italian postmenopausal women according to the National Bone Health Alliance (NBHA) diagnostic criteria: a multicenter cohort study. J Endocrinol Invest 41(4):431\u2013438. https:\/\/doi.org\/10.1007\/s40618-017-0761-4","journal-title":"J Endocrinol Invest"},{"issue":"12","key":"1667_CR10","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1007\/s00198-007-0413-1","volume":"18","author":"C Roux","year":"2007","unstructured":"Roux C, Fechtenbaum J, Kolta S (2007) Mild prevalent and incident vertebral fractures are risk factors for new fractures. Osteoporos Int 18(12):1617\u20131624. https:\/\/doi.org\/10.1007\/s00198-007-0413-1","journal-title":"Osteoporos Int"},{"issue":"7","key":"1667_CR11","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1359\/jbmr.2003.18.7.1254","volume":"18","author":"T Jalava","year":"2003","unstructured":"Jalava T, Sarna S, Pylkk\u00e4nen L (2003) Association between vertebral fracture and increased mortality in osteoporotic patients. J Bone Min Res 18(7):1254\u20131260. https:\/\/doi.org\/10.1359\/jbmr.2003.18.7.1254","journal-title":"J Bone Min Res"},{"issue":"1","key":"1667_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00198-004-1813-0","volume":"16","author":"PD Delmas","year":"2005","unstructured":"Delmas PD, Rizzoli R, Cooper C et al (2005) Treatment of patients with postmenopausal osteoporosis is worthwhile: The position of the International Osteoporosis Foundation. Osteoporos Int 16(1):1\u20135. https:\/\/doi.org\/10.1007\/s00198-004-1813-0","journal-title":"Osteoporos Int"},{"issue":"10","key":"1667_CR13","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1046\/j.1532-5415.2002.50455.x","volume":"50","author":"CL Leibson","year":"2002","unstructured":"Leibson CL, Tosteson ANA, Gabriel SE (2002) Mortality, disability, and nursing home use for persons with and without hip fracture: A population-based study. J Am Geriatr Soc 50(10):1644\u20131650. https:\/\/doi.org\/10.1046\/j.1532-5415.2002.50455.x","journal-title":"J Am Geriatr Soc"},{"issue":"5","key":"1667_CR14","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1053\/berh.2002.0264","volume":"16","author":"KM Jordan","year":"2002","unstructured":"Jordan KM, Cooper C (2002) Epidemiology of osteoporosis. Best Pract Res Clin Rheumatol 16(5):795\u2013806. https:\/\/doi.org\/10.1053\/berh.2002.0264","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"3","key":"1667_CR15","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s00198-016-3868-0","volume":"28","author":"H Johansson","year":"2017","unstructured":"Johansson H, Siggeirsd\u00f3ttir K, Harvey NC (2017) Imminent risk of fracture after fracture. Osteoporos Int 28(3):775\u2013780. https:\/\/doi.org\/10.1007\/s00198-016-3868-0","journal-title":"Osteoporos Int"},{"issue":"2","key":"1667_CR16","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.bone.2004.03.024","volume":"35","author":"JA Kanis","year":"2004","unstructured":"Kanis JA, Johnell O, De Laet C (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone 35(2):375\u2013382. https:\/\/doi.org\/10.1016\/j.bone.2004.03.024","journal-title":"Bone"},{"issue":"10169","key":"1667_CR17","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/S0140-6736(18)32112-3","volume":"393","author":"JE Compston","year":"2019","unstructured":"Compston JE, McClung MR, Leslie WD, Osteoporosis (2019) Lancet 393(10169):364\u2013376. https:\/\/doi.org\/10.1016\/S0140-6736(18)32112-3","journal-title":"Lancet"},{"issue":"4","key":"1667_CR18","doi-asserted-by":"publisher","first-page":"e20162398","DOI":"10.1542\/peds.2016-2398","volume":"138","author":"LK Bachrach","year":"2016","unstructured":"Bachrach LK, Gordon CM (2016) Bone densitometry in children and adolescents. Pediatrics 138(4):e20162398. https:\/\/doi.org\/10.1542\/peds.2016-2398","journal-title":"Pediatrics"},{"issue":"5","key":"1667_CR19","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1359\/jbmr.2001.16.5.901","volume":"16","author":"Y Lu","year":"2001","unstructured":"Lu Y, Genant HK, Shepherd J (2001) Classification of osteoporosis based on bone mineral densities. J Bone Min Res 16(5):901\u2013910. https:\/\/doi.org\/10.1359\/jbmr.2001.16.5.901","journal-title":"J Bone Min Res"},{"issue":"4","key":"1667_CR20","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.mcna.2014.03.007","volume":"98","author":"MA Varacallo","year":"2014","unstructured":"Varacallo MA, Fox EJ (2014) Osteoporosis and its complications. Med Clin North Am 98(4):817\u2013831. https:\/\/doi.org\/10.1016\/j.mcna.2014.03.007","journal-title":"Med Clin North Am"},{"issue":"4","key":"1667_CR21","doi-asserted-by":"publisher","first-page":"101437","DOI":"10.1016\/j.jocd.2023.101437","volume":"31","author":"D Krueger","year":"2023","unstructured":"Krueger D, Tanner SB, Szalat A (2023) DXA reporting updates: 2023 Official Positions of the International Society for Clinical Densitometry. J Clin Densitom 31(4):101437. https:\/\/doi.org\/10.1016\/j.jocd.2023.101437","journal-title":"J Clin Densitom"},{"issue":"6","key":"1667_CR22","doi-asserted-by":"publisher","first-page":"R213","DOI":"10.1530\/EJE-18-0991","volume":"180","author":"C Eller-Vainicher","year":"2019","unstructured":"Eller-Vainicher C, Falchetti A, Gennari L (2019) Diagnosis of endocrine disease: Evaluation of bone fragility in endocrine disorders. Eur J Endocrinol 180(6):R213\u2013R232. https:\/\/doi.org\/10.1530\/EJE-18-0991","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"1667_CR23","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.tem.2020.12.004","volume":"32","author":"AM Formenti","year":"2021","unstructured":"Formenti AM, Dalla Volta A, di Filippo L et al (2021) Effects of Medical Treatment of Prostate Cancer on Bone Health. Trends Endocrinol Metab 32(3):135\u2013158. https:\/\/doi.org\/10.1016\/j.tem.2020.12.004","journal-title":"Trends Endocrinol Metab"},{"issue":"2","key":"1667_CR24","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s11154-023-09792-7","volume":"24","author":"A Giustina","year":"2023","unstructured":"Giustina A, di Filippo L, Allora A et al (2023) Vitamin D and malabsorptive gastrointestinal conditions: A bidirectional relationship? Rev Endocr Metab Disord 24(2):121\u2013138. https:\/\/doi.org\/10.1007\/s11154-023-09792-7","journal-title":"Rev Endocr Metab Disord"},{"issue":"3","key":"1667_CR25","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1007\/s12020-024-03784-6","volume":"85","author":"L di Filippo","year":"2024","unstructured":"di Filippo L, Bilezikian JP, Canalis E et al (2024) New insights into the vitamin D\/PTH axis in endocrine-driven metabolic bone diseases. Endocrine 85(3):1007\u20131019. https:\/\/doi.org\/10.1007\/s12020-024-03784-6","journal-title":"Endocrine"},{"issue":"4","key":"1667_CR26","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s00198-007-0483-0","volume":"19","author":"A Papaioannou","year":"2008","unstructured":"Papaioannou A, Kennedy CC, Ioannidis G et al (2008) The osteoporosis care gap in men with fragility fractures: the Canadian Multicentre Osteoporosis Study. Osteoporos Int 19(4):581\u2013587. https:\/\/doi.org\/10.1007\/s00198-007-0483-0","journal-title":"Osteoporos Int"},{"issue":"4","key":"1667_CR27","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jocd.2014.01.009","volume":"17","author":"M Antonelli","year":"2014","unstructured":"Antonelli M, Einstadter D, Magrey M (2014) Screening and Treatment of Osteoporosis After Hip Fracture: Comparison of Sex and Race. J Clin Densitom 17(4):479\u2013483. https:\/\/doi.org\/10.1016\/j.jocd.2014.01.009","journal-title":"J Clin Densitom"},{"issue":"9","key":"1667_CR28","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","volume":"8","author":"HK Genant","year":"1993","unstructured":"Genant HK, Wu CY, Van Kuijk C et al (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Min Res 8(9):1137\u20131148. https:\/\/doi.org\/10.1002\/jbmr.5650080915","journal-title":"J Bone Min Res"},{"issue":"3","key":"1667_CR29","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1002\/jbmr.3901","volume":"35","author":"N Mikolajewicz","year":"2020","unstructured":"Mikolajewicz N, Bishop N, Burghardt AJ (2020) HR-pQCT measures of bone microarchitecture predict fracture: Systematic review and meta-analysis. J Bone Min Res 35(3):446\u2013459. https:\/\/doi.org\/10.1002\/jbmr.3901","journal-title":"J Bone Min Res"},{"issue":"3","key":"1667_CR30","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/jbmr.2176","volume":"29","author":"BC Silva","year":"2014","unstructured":"Silva BC, Leslie WD, Resch H (2014) Trabecular bone score: A noninvasive analytical method based upon the DXA image. J Bone Min Res 29(3):518\u2013530. https:\/\/doi.org\/10.1002\/jbmr.2176","journal-title":"J Bone Min Res"},{"issue":"11","key":"1667_CR31","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.1002\/jbmr.499","volume":"26","author":"D Hans","year":"2011","unstructured":"Hans D, Goertzen AL, Krieg MA (2011) Bone microarchitecture assessed by TBS predicts osteoporotic fractures independent of bone density: The Manitoba study. J Bone Min Res 26(11):2762\u20132769. https:\/\/doi.org\/10.1002\/jbmr.499","journal-title":"J Bone Min Res"},{"issue":"2","key":"1667_CR32","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00198-020-05557-z","volume":"32","author":"E McCloskey","year":"2021","unstructured":"McCloskey E, Rathi J, Heijmans S (2021) The osteoporosis treatment gap in patients at risk of fracture in European primary care: A multi-country cross-sectional observational study. Osteoporos Int 32(2):251\u2013259. https:\/\/doi.org\/10.1007\/s00198-020-05557-z","journal-title":"Osteoporos Int"},{"issue":"3","key":"1667_CR33","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3390\/targets3030026","volume":"3","author":"F Costanza","year":"2025","unstructured":"Costanza F, Giampietro A, De Marinis L et al (2025) Skeletal health in pituitary and neuroendocrine diseases: Prevention and treatments of bone fragility. Targets 3(3):26. https:\/\/doi.org\/10.3390\/targets3030026","journal-title":"Targets"},{"issue":"4","key":"1667_CR34","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1210\/er.2018-00005","volume":"39","author":"G Mazziotti","year":"2018","unstructured":"Mazziotti G, Frara S, Giustina A (2018) Pituitary diseases and bone. Endocr Rev 39(4):440\u2013488. https:\/\/doi.org\/10.1210\/er.2018-00005","journal-title":"Endocr Rev"},{"key":"1667_CR35","doi-asserted-by":"publisher","first-page":"206853","DOI":"10.1155\/2015\/206853","volume":"2015","author":"M Bolanowski","year":"2015","unstructured":"Bolanowski M, Halupczok J, Jawiarczyk-Przyby\u0142owska A (2015) Pituitary disorders and osteoporosis. Int J Endocrinol 2015:206853. https:\/\/doi.org\/10.1155\/2015\/206853","journal-title":"Int J Endocrinol"},{"issue":"4","key":"1667_CR36","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.tem.2023.01.006","volume":"34","author":"MM Uygur","year":"2023","unstructured":"Uygur MM, Frara S, di Filippo L et al (2023) New tools for bone health assessment in secreting pituitary adenomas. Trends Endocrinol Metab 34(4):231\u2013242. https:\/\/doi.org\/10.1016\/j.tem.2023.01.006","journal-title":"Trends Endocrinol Metab"},{"issue":"2","key":"1667_CR37","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1210\/jc.2014-2937","volume":"100","author":"G Mazziotti","year":"2015","unstructured":"Mazziotti G, Biagioli E, Maffezzoni F (2015) Bone turnover, bone mineral density, and fracture risk in acromegaly: A meta-analysis. J Clin Endocrinol Metab 100(2):384\u2013394. https:\/\/doi.org\/10.1210\/jc.2014-2937","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1667_CR38","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1007\/BF03345496","volume":"25","author":"A Colao","year":"2002","unstructured":"Colao A, Amato G, Pedroncelli AM (2002) Gender- and age-related differences in the endocrine parameters of acromegaly. J Endocrinol Invest 25(6):532\u2013538. https:\/\/doi.org\/10.1007\/BF03345496","journal-title":"J Endocrinol Invest"},{"issue":"12","key":"1667_CR39","doi-asserted-by":"publisher","first-page":"9920","DOI":"10.3390\/ijms24129920","volume":"24","author":"G Voltan","year":"2023","unstructured":"Voltan G, Mazzeo P, Regazzo D (2023) Role of estrogen and estrogen receptor in GH-secreting adenomas. Int J Mol Sci 24(12):9920. https:\/\/doi.org\/10.3390\/ijms24129920","journal-title":"Int J Mol Sci"},{"issue":"19","key":"1667_CR40","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMra2409076","volume":"393","author":"A Giustina","year":"2025","unstructured":"Giustina A, Colao A, Acromegaly (2025) N Engl J Med 393(19):1926\u20131939. https:\/\/doi.org\/10.1056\/NEJMra2409076","journal-title":"N Engl J Med"},{"issue":"6","key":"1667_CR41","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1210\/endrev\/bnac010","volume":"43","author":"S Melmed","year":"2022","unstructured":"Melmed S, Kaiser UB, Lopes MB et al (2022) Clinical Biology of the Pituitary Adenoma. Endocr Rev 43(6):1003\u20131037. https:\/\/doi.org\/10.1210\/endrev\/bnac010","journal-title":"Endocr Rev"},{"issue":"9","key":"1667_CR42","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1007\/BF03349263","volume":"31","author":"A Giustina","year":"2008","unstructured":"Giustina A, Barkan A, Chanson P et al (2008) Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults. J Endocrinol Invest 31(9):820\u2013838. https:\/\/doi.org\/10.1007\/BF03349263","journal-title":"J Endocrinol Invest"},{"issue":"8","key":"1667_CR43","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/BF03346423","volume":"31","author":"A Giustina","year":"2008","unstructured":"Giustina A, Mancini T, Boscani PF et al (2008) Assessment of the awareness and management of cardiovascular complications of acromegaly in Italy. The COM.E.T.A. Study. J Endocrinol Invest 31(8):731\u2013738. https:\/\/doi.org\/10.1007\/BF03346423","journal-title":"J Endocrinol Invest"},{"issue":"15","key":"1667_CR44","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/s0002-9149(99)80721-8","volume":"75","author":"A Giustina","year":"1995","unstructured":"Giustina A, Boni E, Romanelli G et al (1995) Cardiopulmonary performance during exercise in acromegaly, and the effects of acute suppression of growth hormone hypersecretion with octreotide. Am J Cardiol 75(15):1042\u20131047. https:\/\/doi.org\/10.1016\/s0002-9149(99)80721-8","journal-title":"Am J Cardiol"},{"issue":"4","key":"1667_CR45","doi-asserted-by":"publisher","first-page":"dgz096","DOI":"10.1210\/clinem\/dgz096","volume":"105","author":"A Giustina","year":"2020","unstructured":"Giustina A, di Filippo L, Fleseriu M et al (2026) Consensus on acromegaly complications: an update. Pituitary 29(3):76. https:\/\/doi.org\/10.1210\/clinem\/dgz096","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1667_CR46","doi-asserted-by":"publisher","first-page":"R67","DOI":"10.1530\/EJE-19-1023","volume":"182","author":"NF Lenders","year":"2020","unstructured":"Lenders NF, McCormack AI, Ho KKY (2020) Management of endocrine disease: Does gender matter in the management of acromegaly? Eur J Endocrinol 182(5):R67\u2013R82. https:\/\/doi.org\/10.1530\/EJE-19-1023","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"1667_CR47","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/cen.14392","volume":"94","author":"J Dal","year":"2021","unstructured":"Dal J, Skov BG, Andersen M (2021) Sex differences in acromegaly at diagnosis: A nationwide cohort study and meta-analysis of the literature. Clin Endocrinol (Oxf) 94(4):625\u2013635. https:\/\/doi.org\/10.1111\/cen.14392","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"1667_CR48","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/cen.14750","volume":"98","author":"J Dal","year":"2023","unstructured":"Dal J, Rosendal C, Karmisholt J (2023) Sex difference in patients with controlled acromegaly: A multicentre survey. Clin Endocrinol (Oxf) 98(1):74\u201381. https:\/\/doi.org\/10.1111\/cen.14750","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"1667_CR49","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1111\/cen.14828","volume":"97","author":"C Aagaard","year":"2022","unstructured":"Aagaard C, Christophersen AS, Finnerup S (2022) The prevalence of acromegaly is higher than previously reported: Changes over a three-decade period. Clin Endocrinol (Oxf) 97(6):773\u2013782. https:\/\/doi.org\/10.1111\/cen.14828","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"1667_CR50","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1530\/EJE-16-0117","volume":"175","author":"J Dal","year":"2016","unstructured":"Dal J, Feldt-Rasmussen U, Andersen M (2016) Acromegaly incidence, prevalence, complications, and long-term prognosis: A nationwide cohort study. Eur J Endocrinol 175(3):181\u2013190. https:\/\/doi.org\/10.1530\/EJE-16-0117","journal-title":"Eur J Endocrinol"},{"key":"1667_CR51","doi-asserted-by":"publisher","first-page":"2018464","DOI":"10.1155\/2020\/2018464","volume":"2020","author":"X Guo","year":"2020","unstructured":"Guo X, Cao J, Liu P (2020) Cardiac abnormalities in acromegaly patients: A cardiac magnetic resonance study. Int J Endocrinol 2020:2018464. https:\/\/doi.org\/10.1155\/2020\/2018464","journal-title":"Int J Endocrinol"},{"issue":"3","key":"1667_CR52","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s11102-015-0702-1","volume":"19","author":"I Kreitschmann-Andermahr","year":"2016","unstructured":"Kreitschmann-Andermahr I, Siegel S, Kleist B (2016) Diagnosis and management of acromegaly: The patient\u2019s perspective. Pituitary 19(3):268\u2013276. https:\/\/doi.org\/10.1007\/s11102-015-0702-1","journal-title":"Pituitary"},{"issue":"4","key":"1667_CR53","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s11102-012-0447-z","volume":"16","author":"S Siegel","year":"2013","unstructured":"Siegel S, Streetz-van der Werf C, Schott JS (2013) Diagnostic delay is associated with psychosocial impairment in acromegaly. Pituitary 16(4):507\u2013514. https:\/\/doi.org\/10.1007\/s11102-012-0447-z","journal-title":"Pituitary"},{"issue":"10","key":"1667_CR54","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1530\/ERC-17-0253","volume":"24","author":"P Petrossians","year":"2017","unstructured":"Petrossians P, Daly AF, Natchev E (2017) Acromegaly at diagnosis in 3173 patients from the Li\u00e8ge Acromegaly Survey (LAS) Database. Endocr Relat Cancer 24(10):505\u2013518. https:\/\/doi.org\/10.1530\/ERC-17-0253","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"1667_CR55","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s11102-025-01586-1","volume":"28","author":"M Araujo-Castro","year":"2025","unstructured":"Araujo-Castro M, Garc\u00eda-Centeno R, Gonz\u00e1lez L et al (2025) Prevalence and evolution of hypertension in a large Iberian cohort of patients with acromegaly. Pituitary 28(6):119. https:\/\/doi.org\/10.1007\/s11102-025-01586-1","journal-title":"Pituitary"},{"issue":"8","key":"1667_CR56","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1159\/000511811","volume":"111","author":"M Cellini","year":"2021","unstructured":"Cellini M, Biamonte E, Mazza M (2021) Vertebral fractures associated with spinal sagittal imbalance and quality of life in acromegaly: A radiographic study with EOS 2D\/3D technology. Neuroendocrinology 111(8):775\u2013785. https:\/\/doi.org\/10.1159\/000511811","journal-title":"Neuroendocrinology"},{"issue":"1","key":"1667_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3803\/EnM.2024.2285","volume":"40","author":"S Hong","year":"2025","unstructured":"Hong S, Han K, Park CY (2025) Long-term prognosis and systemic impact of acromegaly: Analyses utilizing Korean National Health Insurance data. Endocrinol Metab 40(1):1\u20139. https:\/\/doi.org\/10.3803\/EnM.2024.2285","journal-title":"Endocrinol Metab"},{"issue":"3","key":"1667_CR58","doi-asserted-by":"publisher","first-page":"e00229","DOI":"10.1002\/edm2.229","volume":"4","author":"D Ballesteros-Herrera","year":"2021","unstructured":"Ballesteros-Herrera D, Brise\u00f1o-Hern\u00e1ndez P, P\u00e9rez-Esparza R et al (2021) Differences in quality of life between genders in acromegaly. Endocrinol Diabetes Metab 4(3):e00229. https:\/\/doi.org\/10.1002\/edm2.229","journal-title":"Endocrinol Diabetes Metab"},{"key":"1667_CR59","doi-asserted-by":"publisher","first-page":"899","DOI":"10.3389\/fendo.2019.00899","volume":"10","author":"A Jawiarczyk-Przyby\u0142owska","year":"2020","unstructured":"Jawiarczyk-Przyby\u0142owska A, Szcze\u015bniak D, Ciu\u0142kowicz M (2020) Importance of illness acceptance among other factors affecting quality of life in acromegaly. Front Endocrinol 10:899. https:\/\/doi.org\/10.3389\/fendo.2019.00899","journal-title":"Front Endocrinol"},{"issue":"3","key":"1667_CR60","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s12020-022-03106-8","volume":"77","author":"B Cangiano","year":"2022","unstructured":"Cangiano B, Giusti E, Premoli C et al (2022) Psychological complications in patients with acromegaly: relationships with sex, arthropathy, and quality of life. Endocrine 77(3):510\u2013518. https:\/\/doi.org\/10.1007\/s12020-022-03106-8","journal-title":"Endocrine"},{"issue":"10","key":"1667_CR61","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/BF03347356","volume":"29","author":"M Bolanowski","year":"2006","unstructured":"Bolanowski M, Daroszewski J, St\u0119pie\u0144-K\u0142os W (2006) BMD and turnover in acromegalic patients with and without vertebral fractures. J Endocrinol Invest 29(10):819\u2013824. https:\/\/doi.org\/10.1007\/BF03347356","journal-title":"J Endocrinol Invest"},{"issue":"6","key":"1667_CR62","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1046\/j.1365-2265.2003.01767.x","volume":"58","author":"A Scillitani","year":"2003","unstructured":"Scillitani A, Battista C, Chiodini I (2003) Bone mineral density in acromegaly: The effect of sex, disease activity, and gonadal status. Clin Endocrinol (Oxf) 58(6):725\u2013731. https:\/\/doi.org\/10.1046\/j.1365-2265.2003.01767.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"1667_CR63","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s12020-023-03317-7","volume":"80","author":"A Giustina","year":"2023","unstructured":"Giustina A, di Filippo L, Uygur MM et al (2023) Modern approach to resistant acromegaly. Endocrine 80(2):303\u2013307. https:\/\/doi.org\/10.1007\/s12020-023-03317-7","journal-title":"Endocrine"},{"issue":"11","key":"1667_CR64","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/s41574-025-01148-2","volume":"21","author":"S Melmed","year":"2025","unstructured":"Melmed S, di Filippo L, Fleseriu M et al (2025) Consensus on acromegaly therapeutic outcomes: an update. Nat Rev Endocrinol 21(11):718\u2013737. https:\/\/doi.org\/10.1038\/s41574-025-01148-2","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"1667_CR65","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1530\/EJE-16-1064","volume":"176","author":"L Maione","year":"2017","unstructured":"Maione L, Brue T, Beckers A (2017) Changes in the management and comorbidities of acromegaly over three decades: The French Acromegaly Registry. Eur J Endocrinol 176(5):645\u2013655. https:\/\/doi.org\/10.1530\/EJE-16-1064","journal-title":"Eur J Endocrinol"},{"key":"1667_CR66","doi-asserted-by":"publisher","first-page":"627711","DOI":"10.3389\/fendo.2021.627711","volume":"12","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M, Molitch M, Dreval A (2021) Disease- and treatment-related burden in patients with acromegaly who are biochemically controlled on injectable somatostatin receptor ligands. Front Endocrinol 12:627711. https:\/\/doi.org\/10.3389\/fendo.2021.627711","journal-title":"Front Endocrinol"},{"issue":"6","key":"1667_CR67","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s11102-024-01464-2","volume":"27","author":"S Bolamperti","year":"2024","unstructured":"Bolamperti S, Villa I, di Filippo L (2024) Growth hormone and bone: a basic perspective. Pituitary 27(6):745\u2013751. https:\/\/doi.org\/10.1007\/s11102-024-01464-2","journal-title":"Pituitary"},{"issue":"7","key":"1667_CR68","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1002\/jbmr.1920","volume":"28","author":"Y Wu","year":"2013","unstructured":"Wu Y, Sun H, Basta-Pljakic J et al (2013) Serum IGF\u20101 Is Insufficient to Restore Skeletal Size in the Total Absence of the Growth Hormone Receptor. J Bone Min Res 28(7):1575\u20131586. https:\/\/doi.org\/10.1002\/jbmr.1920","journal-title":"J Bone Min Res"},{"issue":"4","key":"1667_CR69","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1210\/en.2014-1572","volume":"156","author":"SV Lim","year":"2015","unstructured":"Lim SV, Marenzana M, Hopkinson M et al (2015) Excessive Growth Hormone Expression in Male GH Transgenic Mice Adversely Alters Bone Architecture and Mechanical Strength. Endocrinology 156(4):1362\u20131371. https:\/\/doi.org\/10.1210\/en.2014-1572","journal-title":"Endocrinology"},{"issue":"5","key":"1667_CR70","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1359\/JBMR.040308","volume":"19","author":"F Eckstein","year":"2004","unstructured":"Eckstein F, Weusten A, Schmidt C et al (2004) Longitudinal in vivo effects of growth hormone overexpression on bone in transgenic mice. J Bone Min Res 19(5):802\u2013810. https:\/\/doi.org\/10.1359\/JBMR.040308","journal-title":"J Bone Min Res"},{"issue":"11","key":"1667_CR71","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1002\/jbmr.4699","volume":"37","author":"M Dixit","year":"2022","unstructured":"Dixit M, Louis LD, Basta-Pljakic J et al (2022) Lifelong Excess in GH Elicits Sexually Dimorphic Effects on Skeletal Morphology and Bone Mechanical Properties. J Bone Min Res 37(11):2201\u20132214. https:\/\/doi.org\/10.1002\/jbmr.4699","journal-title":"J Bone Min Res"},{"issue":"5","key":"1667_CR72","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1210\/en.2007-1068","volume":"149","author":"VE DeMambro","year":"2008","unstructured":"DeMambro VE, Clemmons DR, Horton LG et al (2008) Gender-specific changes in bone turnover and skeletal architecture in igfbp-2-null mice. Endocrinology 149(5):2051\u20132061. https:\/\/doi.org\/10.1210\/en.2007-1068","journal-title":"Endocrinology"},{"issue":"1","key":"1667_CR73","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1530\/JOE-16-0673","volume":"233","author":"DE Maridas","year":"2017","unstructured":"Maridas DE, DeMambro VE, Le PT et al (2017) IGFBP-4 regulates adult skeletal growth in a sex-specific manner. J Endocrinol 233(1):131\u2013144. https:\/\/doi.org\/10.1530\/JOE-16-0673","journal-title":"J Endocrinol"},{"issue":"4","key":"1667_CR74","doi-asserted-by":"publisher","first-page":"E734","DOI":"10.1152\/ajpendo.1997.273.4.E734","volume":"273","author":"JK Yeh","year":"1997","unstructured":"Yeh JK, Chen MM, Aloia JF (1997) Effects of estrogen and growth hormone on skeleton in the ovariectomized rat with hypophysectomy. Am J Physiol 273(4):E734\u2013742. https:\/\/doi.org\/10.1152\/ajpendo.1997.273.4.E734","journal-title":"Am J Physiol"},{"issue":"1","key":"1667_CR75","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.bone.2013.03.016","volume":"55","author":"S Bolamperti","year":"2013","unstructured":"Bolamperti S, Mrak E, Moro G et al (2013) 17\u03b2-Estradiol positively modulates growth hormone signaling through the reduction of SOCS2 negative feedback in human osteoblasts. Bone 55(1):84\u201392. https:\/\/doi.org\/10.1016\/j.bone.2013.03.016","journal-title":"Bone"},{"issue":"1","key":"1667_CR76","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1359\/jbmr.2003.18.1.150","volume":"18","author":"BT Kim","year":"2003","unstructured":"Kim BT, Mosekilde L, Duan Y et al (2003) The structural and hormonal basis of sex differences in peak appendicular bone strength in rats. J Bone Min Res 18(1):150\u2013155. https:\/\/doi.org\/10.1359\/jbmr.2003.18.1.150","journal-title":"J Bone Min Res"},{"issue":"4","key":"1667_CR77","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.tem.2020.01.011","volume":"31","author":"A Giustina","year":"2020","unstructured":"Giustina A (2020) Acromegaly and Vertebral Fractures: Facts and Questions. Trends Endocrinol Metab 31(4):274\u2013275. https:\/\/doi.org\/10.1016\/j.tem.2020.01.011","journal-title":"Trends Endocrinol Metab"},{"issue":"6","key":"1667_CR78","doi-asserted-by":"publisher","first-page":"655","DOI":"10.3803\/EnM.2023.601","volume":"38","author":"A Giustina","year":"2023","unstructured":"Giustina A (2023) Acromegaly and Bone: An Update. Endocrinol Metab (Seoul) 38(6):655\u2013666. https:\/\/doi.org\/10.3803\/EnM.2023.601","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"9","key":"1667_CR79","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1210\/clinem\/dgab317","volume":"106","author":"BC Silva","year":"2021","unstructured":"Silva BC, Pereira RMR, Takayama L (2021) Impaired bone microarchitecture in premenopausal women with acromegaly: The possible role of Wnt signaling. J Clin Endocrinol Metab 106(9):2690\u20132706. https:\/\/doi.org\/10.1210\/clinem\/dgab317","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1667_CR80","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1210\/jc.2012-3658","volume":"98","author":"M Madeira","year":"2013","unstructured":"Madeira M, Neto LV, de Paula Paranhos Neto F (2013) Acromegaly adversely affects trabecular bone but not cortical bone, as assessed by high-resolution peripheral quantitative computed tomography. J Clin Endocrinol Metab 98(4):1734\u20131741. https:\/\/doi.org\/10.1210\/jc.2012-3658","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1667_CR81","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1530\/EJE-15-0849","volume":"174","author":"E Valassi","year":"2016","unstructured":"Valassi E, Crespo I, Malouf J (2016) Reduction of trabecular and cortical volumetric bone mineral density at the proximal femur in patients with acromegaly. Eur J Endocrinol 174(2):107\u2013114. https:\/\/doi.org\/10.1530\/EJE-15-0849","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"1667_CR82","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1007\/s12020-016-1019-z","volume":"54","author":"F Maffezzoni","year":"2016","unstructured":"Maffezzoni F, Maddalo M, Frara S (2016) High-resolution cone beam tomography analysis of bone microarchitecture in patients with acromegaly and radiological vertebral fractures. Endocrine 54(2):532\u2013540. https:\/\/doi.org\/10.1007\/s12020-016-1019-z","journal-title":"Endocrine"},{"issue":"1","key":"1667_CR83","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s11102-017-0851-5","volume":"21","author":"L Dalle Carbonare","year":"2018","unstructured":"Dalle Carbonare L, Micheletti V, Cosaro E (2018) Bone histomorphometry in acromegaly patients with fragility vertebral fractures. Pituitary 21(1):56\u201364. https:\/\/doi.org\/10.1007\/s11102-017-0851-5","journal-title":"Pituitary"},{"issue":"3","key":"1667_CR84","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1530\/EJE-16-0796","volume":"176","author":"F Malgo","year":"2017","unstructured":"Malgo F, Hamdy NAT, Rabelink TJ (2017) Bone material strength index (BMSi), as measured by impact microindentation, is altered in patients with acromegaly. Eur J Endocrinol 176(3):339\u2013347. https:\/\/doi.org\/10.1530\/EJE-16-0796","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"1667_CR85","doi-asserted-by":"publisher","first-page":"e10240","DOI":"10.1002\/jbm4.10240","volume":"3","author":"K Godang","year":"2019","unstructured":"Godang K, Lekva T, Normann KR (2019) Hip structure analyses in acromegaly: Decrease of cortical bone thickness after treatment: A longitudinal cohort study. JBMR Plus 3(12):e10240. https:\/\/doi.org\/10.1002\/jbm4.10240","journal-title":"JBMR Plus"},{"issue":"1","key":"1667_CR86","doi-asserted-by":"publisher","first-page":"164","DOI":"10.3390\/jcm12010164","volume":"12","author":"MC Sorohan","year":"2022","unstructured":"Sorohan MC, Poian\u0103 C (2022) Vertebral fractures in acromegaly: A systematic review. J Clin Med 12(1):164. https:\/\/doi.org\/10.3390\/jcm12010164","journal-title":"J Clin Med"},{"issue":"7","key":"1667_CR87","doi-asserted-by":"publisher","first-page":"e2843","DOI":"10.1210\/clinem\/dgac183","volume":"107","author":"S Frara","year":"2022","unstructured":"Frara S, Melin Uygur M, di Filippo L et al (2022) High Prevalence of Vertebral Fractures Associated With Preoperative GH Levels in Patients With Recent Diagnosis of Acromegaly. J Clin Endocrinol Metab 107(7):e2843\u2013e2850. https:\/\/doi.org\/10.1210\/clinem\/dgac183","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1667_CR88","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1530\/EJE-10-1016","volume":"164","author":"MJE Wassenaar","year":"2011","unstructured":"Wassenaar MJE, Biermasz NR, Hamdy NAT (2011) High prevalence of vertebral fractures despite normal bone mineral density in patients with long-term controlled acromegaly. Eur J Endocrinol 164(4):475\u2013483. https:\/\/doi.org\/10.1530\/EJE-10-1016","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"1667_CR89","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1359\/JBMR.050608","volume":"20","author":"S Bonadonna","year":"2005","unstructured":"Bonadonna S, Mazziotti G, Nuzzo M (2005) Increased prevalence of radiological spinal deformities in active acromegaly: A cross-sectional study in postmenopausal women. J Bone Min Res 20(10):1837\u20131844. https:\/\/doi.org\/10.1359\/JBMR.050608","journal-title":"J Bone Min Res"},{"issue":"8","key":"1667_CR90","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1210\/jc.2013-1529","volume":"98","author":"G Mazziotti","year":"2013","unstructured":"Mazziotti G, Bianchi A, Porcelli T (2013) Vertebral fractures in patients with acromegaly: A 3-year prospective study. J Clin Endocrinol Metab 98(8):3402\u20133410. https:\/\/doi.org\/10.1210\/jc.2013-1529","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1667_CR91","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1530\/EJE-20-0348","volume":"183","author":"ICM Pelsma","year":"2020","unstructured":"Pelsma ICM, Biermasz NR, Pereira AM (2020) Progression of vertebral fractures in long-term controlled acromegaly: A 9-year follow-up study. Eur J Endocrinol 183(4):427\u2013437. https:\/\/doi.org\/10.1530\/EJE-20-0348","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"1667_CR92","doi-asserted-by":"publisher","first-page":"690","DOI":"10.3803\/EnM.2023.1705","volume":"38","author":"J Kim","year":"2023","unstructured":"Kim J, Hong N, Choi J (2023) Increased risk of hip fracture in patients with acromegaly: A nationwide cohort study in Korea. Endocrinol Metab 38(6):690\u2013700. https:\/\/doi.org\/10.3803\/EnM.2023.1705","journal-title":"Endocrinol Metab"},{"issue":"12","key":"1667_CR93","doi-asserted-by":"publisher","first-page":"4808","DOI":"10.1210\/jc.2013-2702","volume":"98","author":"KMJA Claessen","year":"2013","unstructured":"Claessen KMJA, Kroon HM, Pereira AM (2013) Progression of vertebral fractures despite long-term biochemical control of acromegaly: A prospective follow-up study. J Clin Endocrinol Metab 98(12):4808\u20134815. https:\/\/doi.org\/10.1210\/jc.2013-2702","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1667_CR94","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1159\/000375450","volume":"103","author":"KMJA Claessen","year":"2016","unstructured":"Claessen KMJA, Mazziotti G, Biermasz NR et al (2016) Bone and Joint Disorders in Acromegaly. Neuroendocrinology 103(1):86\u201395. https:\/\/doi.org\/10.1159\/000375450","journal-title":"Neuroendocrinology"},{"issue":"8","key":"1667_CR95","doi-asserted-by":"publisher","first-page":"bvab090","DOI":"10.1210\/jendso\/bvab090","volume":"5","author":"E Sala","year":"2021","unstructured":"Sala E, Malchiodi E, Verrua E (2021) Spine bone texture assessed by trabecular bone score in active and controlled acromegaly: A prospective study. J Endocr Soc 5(8):bvab090. https:\/\/doi.org\/10.1210\/jendso\/bvab090","journal-title":"J Endocr Soc"},{"issue":"11","key":"1667_CR96","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.1007\/s00198-016-3652-1","volume":"27","author":"AR Hong","year":"2016","unstructured":"Hong AR, Kim JH, Kim JH (2016) Trabecular bone score as a skeletal fragility index in patients with acromegaly. Osteoporos Int 27(11):3271\u20133277. https:\/\/doi.org\/10.1007\/s00198-016-3652-1","journal-title":"Osteoporos Int"},{"issue":"1","key":"1667_CR97","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/cen.14409","volume":"95","author":"M Calatayud","year":"2021","unstructured":"Calatayud M, P\u00e9rez-Olivares L, Librizzi MS (2021) Trabecular bone score and bone mineral density in patients with long-term controlled acromegaly: A cross-sectional study. Clin Endocrinol (Oxf) 95(1):58\u201364. https:\/\/doi.org\/10.1111\/cen.14409","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"21","key":"1667_CR98","doi-asserted-by":"publisher","first-page":"6374","DOI":"10.3390\/jcm11216374","volume":"11","author":"E Nazzari","year":"2022","unstructured":"Nazzari E, Casabella A, Brevi F (2022) Trabecular bone score as a reliable measure of lumbar spine bone microarchitecture in acromegalic patients. J Clin Med 11(21):6374. https:\/\/doi.org\/10.3390\/jcm11216374","journal-title":"J Clin Med"},{"issue":"4","key":"1667_CR99","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1159\/000528221","volume":"113","author":"F Bioletto","year":"2023","unstructured":"Bioletto F, De Filippis T, Brancatella A (2023) Trabecular bone score as an index of bone fragility in patients with acromegaly: A systematic review and meta-analysis. Neuroendocrinology 113(4):395\u2013409. https:\/\/doi.org\/10.1159\/000528221","journal-title":"Neuroendocrinology"},{"issue":"6","key":"1667_CR100","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s11102-022-01266-4","volume":"25","author":"S Chiloiro","year":"2022","unstructured":"Chiloiro S, Giampietro A, Gagliardi I et al (2022) Impact of the diagnostic delay of acromegaly on bone health: data from a real life and long term follow-up experience. Pituitary 25(6):831\u2013841. https:\/\/doi.org\/10.1007\/s11102-022-01266-4","journal-title":"Pituitary"},{"issue":"6","key":"1667_CR101","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1007\/s11102-025-01573-6","volume":"28","author":"S Chiloiro","year":"2025","unstructured":"Chiloiro S, Palumbo C, Giampietro A et al (2025) Acromegaly treatment and bone: a bidirectional relationship. Pituitary 28(6):124. https:\/\/doi.org\/10.1007\/s11102-025-01573-6","journal-title":"Pituitary"},{"issue":"6","key":"1667_CR102","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s11102-024-01424-w","volume":"27","author":"S Frara","year":"2024","unstructured":"Frara S, Acanfora M, Franzese V (2024) Novel approach to bone comorbidity in resistant acromegaly. Pituitary 27(6):813\u2013823. https:\/\/doi.org\/10.1007\/s11102-024-01424-w","journal-title":"Pituitary"},{"key":"1667_CR103","doi-asserted-by":"publisher","unstructured":"Chiloiro S, Giampietro A, Frara S et al (2020) Effects of Pegvisomant and Pasireotide LAR on Vertebral Fractures in Acromegaly Resistant to First-generation SRLs. J Clin Endocrinol Metab 105(3):dgz054. https:\/\/doi.org\/10.1210\/clinem\/dgz054","DOI":"10.1210\/clinem\/dgz054"},{"key":"1667_CR104","doi-asserted-by":"publisher","unstructured":"Chiloiro S, Frara S, Gagliardi I et al (2023) Cholecalciferol Use Is Associated With a Decreased Risk of Incident Morphometric Vertebral Fractures in Acromegaly. J Clin Endocrinol Metab 109(1):e58\u2013e68. https:\/\/doi.org\/10.1210\/clinem\/dgad493","DOI":"10.1210\/clinem\/dgad493"},{"key":"1667_CR105","doi-asserted-by":"publisher","unstructured":"Chiloiro S, Costanza F, Vicari A, et al. Long-term effect on bone mineral density of denosumab in the treatment of hyperpituitarism driven osteoporosis: an exploratory study. Pituitary. 2026;29(1):31. https:\/\/doi.org\/10.1007\/s11102-025-01630-0","DOI":"10.1007\/s11102-025-01630-0"},{"key":"1667_CR106","doi-asserted-by":"publisher","first-page":"505","DOI":"10.2147\/TCRM.S12952","volume":"6","author":"T Mancini","year":"2010","unstructured":"Mancini T, Porcelli T, Giustina A (2010) Treatment of Cushing disease: overview and recent findings. Ther Clin Risk Manag 6:505\u2013516. https:\/\/doi.org\/10.2147\/TCRM.S12952","journal-title":"Ther Clin Risk Manag"},{"issue":"12","key":"1667_CR107","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S2213-8587(21)00235-7","volume":"9","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M, Auchus R, Bancos I et al (2021) Consensus on diagnosis and management of Cushing\u2019s disease: a guideline update. Lancet Diabetes Endocrinol 9(12):847\u2013875. https:\/\/doi.org\/10.1016\/S2213-8587(21)00235-7","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"1667_CR108","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/cen.12299","volume":"80","author":"M Zilio","year":"2014","unstructured":"Zilio M, Barbot M, Ceccato F (2014) Diagnosis and complications of Cushing\u2019s disease: Gender-related differences. Clin Endocrinol (Oxf) 80(3):403\u2013410. https:\/\/doi.org\/10.1111\/cen.12299","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"7","key":"1667_CR109","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S2213-8587(16)00086-3","volume":"4","author":"R Pivonello","year":"2016","unstructured":"Pivonello R, Isidori AM, De Martino MC (2016) Complications of Cushing\u2019s syndrome: State of the art. Lancet Diabetes Endocrinol 4(7):611\u2013629. https:\/\/doi.org\/10.1016\/S2213-8587(16)00086-3","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"1667_CR110","doi-asserted-by":"publisher","first-page":"55","DOI":"10.5144\/0256-4947.2024.55","volume":"44","author":"BF Alqeeq","year":"2024","unstructured":"Alqeeq BF, Ayyad M, Almadhoun WJ (2024) Sex-related differences in Cushing\u2019s disease: A systematic review and meta-analysis. Ann Saudi Med 44(1):55\u201365. https:\/\/doi.org\/10.5144\/0256-4947.2024.55","journal-title":"Ann Saudi Med"},{"issue":"4","key":"1667_CR111","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1210\/jc.2002-021518","volume":"88","author":"F Pecori Giraldi","year":"2003","unstructured":"Pecori Giraldi F, Moro M, Cavagnini F (2003) Gender-related differences in the presentation and course of Cushing\u2019s disease. J Clin Endocrinol Metab 88(4):1554\u20131558. https:\/\/doi.org\/10.1210\/jc.2002-021518","journal-title":"J Clin Endocrinol Metab"},{"key":"1667_CR112","doi-asserted-by":"publisher","first-page":"580","DOI":"10.3389\/fendo.2019.00580","volume":"10","author":"LHA Broersen","year":"2019","unstructured":"Broersen LHA, van Haalen FM, Kienitz T (2019) Sex differences in presentation but not in outcome for ACTH-dependent Cushing\u2019s syndrome. Front Endocrinol 10:580. https:\/\/doi.org\/10.3389\/fendo.2019.00580","journal-title":"Front Endocrinol"},{"issue":"5","key":"1667_CR113","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1210\/jc.2005-0582","volume":"91","author":"L Tauchmanov\u00e0","year":"2006","unstructured":"Tauchmanov\u00e0 L, Pivonello R, Di Somma C (2006) Bone demineralization and vertebral fractures in endogenous cortisol excess: Role of disease etiology and gonadal status. J Clin Endocrinol Metab 91(5):1779\u20131784. https:\/\/doi.org\/10.1210\/jc.2005-0582","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1667_CR114","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s11102-024-01427-7","volume":"27","author":"A Zdrojowy-We\u0142na","year":"2024","unstructured":"Zdrojowy-We\u0142na A, Stachowska B, Bolanowski M (2024) Cushing\u2019s disease and bone. Pituitary 27(6):837\u2013846. https:\/\/doi.org\/10.1007\/s11102-024-01427-7","journal-title":"Pituitary"},{"issue":"22","key":"1667_CR115","doi-asserted-by":"publisher","first-page":"3948","DOI":"10.3760\/cma.j.issn.0366-6999.20141982","volume":"127","author":"Y Chen","year":"2014","unstructured":"Chen Y, Mei X, Jian F (2014) Gender and magnetic resonance imaging classification-related differences in clinical and biochemical characteristics of Cushing\u2019s disease: A single-centre study. Chin Med J (Engl) 127(22):3948\u20133956. https:\/\/doi.org\/10.3760\/cma.j.issn.0366-6999.20141982","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"1667_CR116","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1093\/ejendo\/lvae004","volume":"190","author":"A Giuliodori","year":"2024","unstructured":"Giuliodori A, Soudah E, Malouf J (2024) Evaluation of bone-related mechanical properties in female patients with long-term remission of Cushing\u2019s syndrome using quantitative computed tomography-based finite element analysis. Eur J Endocrinol 190(1):86\u201395. https:\/\/doi.org\/10.1093\/ejendo\/lvae004","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"1667_CR117","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/jbm4.10009","volume":"1","author":"J Williams-Dautovich","year":"2017","unstructured":"Williams-Dautovich J, Yogendirarajah K, Dela Cruz A et al (2017) The CRH-Transgenic Cushingoid Mouse Is a Model of Glucocorticoid-Induced Osteoporosis. JBMR Plus 1(1):46\u201357. https:\/\/doi.org\/10.1002\/jbm4.10009","journal-title":"JBMR Plus"},{"issue":"4","key":"1667_CR118","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.jds.2015.07.001","volume":"10","author":"T Sato","year":"2015","unstructured":"Sato T, Sano Y, Niimura M et al (2015) Adrenocorticotropic hormone at pathophysiological concentration modulates the proliferation and differentiation of bone cells. J Dent Sci 10(4):456\u2013461. https:\/\/doi.org\/10.1016\/j.jds.2015.07.001","journal-title":"J Dent Sci"},{"issue":"2","key":"1667_CR119","doi-asserted-by":"publisher","first-page":"101515","DOI":"10.1016\/j.beem.2021.101515","volume":"35","author":"S Frara","year":"2021","unstructured":"Frara S, Allora A, di Filippo L et al (2021) Osteopathy in mild adrenal Cushing\u2019s syndrome and Cushing disease. Best Pract Res Clin Endocrinol Metab 35(2):101515. https:\/\/doi.org\/10.1016\/j.beem.2021.101515","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"5","key":"1667_CR120","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1007\/s11102-022-01252-w","volume":"25","author":"S Frara","year":"2022","unstructured":"Frara S, di Filippo L, Doga M et al (2022) Novel approaches to bone comorbidity in Cushing\u2019s disease: an update. Pituitary 25(5):754\u2013759. https:\/\/doi.org\/10.1007\/s11102-022-01252-w","journal-title":"Pituitary"},{"issue":"1","key":"1667_CR121","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1507\/endocrj.50.1","volume":"50","author":"N Ohmori","year":"2003","unstructured":"Ohmori N, Nomura K, Ohmori K (2003) Osteoporosis is more prevalent in adrenal than in pituitary Cushing\u2019s syndrome. Endocr J 50(1):1\u20137. https:\/\/doi.org\/10.1507\/endocrj.50.1","journal-title":"Endocr J"},{"issue":"11","key":"1667_CR122","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s00198-004-1616-3","volume":"15","author":"M Minetto","year":"2004","unstructured":"Minetto M, Reimondo G, Osella G (2004) Bone loss is more severe in primary adrenal than in pituitary-dependent Cushing\u2019s syndrome. Osteoporos Int 15(11):855\u2013861. https:\/\/doi.org\/10.1007\/s00198-004-1616-3","journal-title":"Osteoporos Int"},{"issue":"8","key":"1667_CR123","doi-asserted-by":"publisher","first-page":"e42911","DOI":"10.7759\/cureus.42911","volume":"15","author":"MS Baba","year":"2023","unstructured":"Baba MS, Islam Mir SU, Bhat MH et al (2023) Gender disparities in prolactinomas: Unravelling clinical patterns, metabolic variations, and treatment responses. Cureus 15(8):e42911. https:\/\/doi.org\/10.7759\/cureus.42911","journal-title":"Cureus"},{"key":"1667_CR124","doi-asserted-by":"publisher","first-page":"1338345","DOI":"10.3389\/fendo.2024.1338345","volume":"15","author":"L Dzialach","year":"2024","unstructured":"Dzialach L, Sobolewska J, Zak Z et al (2024) Prolactin-secreting pituitary adenomas: Male-specific differences in pathogenesis, clinical presentation and treatment. Front Endocrinol 15:1338345. https:\/\/doi.org\/10.3389\/fendo.2024.1338345","journal-title":"Front Endocrinol"},{"issue":"4","key":"1667_CR125","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.3390\/ijms25041976","volume":"25","author":"D Szukiewicz","year":"2024","unstructured":"Szukiewicz D (2024) Current insights in prolactin signaling and ovulatory function. Int J Mol Sci 25(4):1976. https:\/\/doi.org\/10.3390\/ijms25041976","journal-title":"Int J Mol Sci"},{"issue":"2","key":"1667_CR126","doi-asserted-by":"publisher","first-page":"101290","DOI":"10.1016\/j.beem.2019.101290","volume":"33","author":"P Chanson","year":"2019","unstructured":"Chanson P, Maiter D (2019) The epidemiology, diagnosis and treatment of prolactinomas: The old and the new. Best Pract Res Clin Endocrinol Metab 33(2):101290. https:\/\/doi.org\/10.1016\/j.beem.2019.101290","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"11","key":"1667_CR127","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.4065\/73.11.1046","volume":"73","author":"Calle-Rodrigue","year":"1998","unstructured":"Calle-Rodrigue RD, Giannini C, Scheithauer BW (1998) Prolactinomas in male and female patients: A comparative clinicopathologic study. Mayo Clin Proc 73(11):1046\u20131056. https:\/\/doi.org\/10.4065\/73.11.1046","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"1667_CR128","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1055\/s-0037-1615748","volume":"79","author":"F Yoo","year":"2018","unstructured":"Yoo F, Chan C, Kuan EC et al (2018) Comparison of male and female prolactinoma patients requiring surgical intervention. J Neurol Surg Part B Skull Base 79(4):394\u2013400. https:\/\/doi.org\/10.1055\/s-0037-1615748","journal-title":"J Neurol Surg Part B Skull Base"},{"issue":"5","key":"1667_CR129","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s00234-002-0774-2","volume":"44","author":"H Nishioka","year":"2002","unstructured":"Nishioka H, Haraoka J, Akada K et al (2002) Gender-related differences in prolactin secretion in pituitary prolactinomas. Neuroradiology 44(5):407\u2013410. https:\/\/doi.org\/10.1007\/s00234-002-0774-2","journal-title":"Neuroradiology"},{"issue":"8","key":"1667_CR130","doi-asserted-by":"publisher","first-page":"103102","DOI":"10.1016\/j.arcmed.2024.103102","volume":"55","author":"F Haidenberg-David","year":"2024","unstructured":"Haidenberg-David F, Sidauy-Adissi J, Moscona-Nissan A (2024) Overview of hyperprolactinemia: General approach and reproductive health implications. Arch Med Res 55(8):103102. https:\/\/doi.org\/10.1016\/j.arcmed.2024.103102","journal-title":"Arch Med Res"},{"issue":"3","key":"1667_CR131","doi-asserted-by":"publisher","first-page":"204","DOI":"10.2174\/0115748871288948240325080936","volume":"19","author":"O Voznyak","year":"2024","unstructured":"Voznyak O, Zinkevych I, Lytvynenko A et al (2024) Gender differences in patients with prolactinoma: Single-center Ukrainian experience. Rev Recent Clin Trials 19(3):204\u2013214. https:\/\/doi.org\/10.2174\/0115748871288948240325080936","journal-title":"Rev Recent Clin Trials"},{"issue":"3","key":"1667_CR132","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1530\/eje.0.1480325","volume":"148","author":"A Colao","year":"2003","unstructured":"Colao A, Sarno AD, Cappabianca P (2003) Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol 148(3):325\u2013331. https:\/\/doi.org\/10.1530\/eje.0.1480325","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"1667_CR133","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1530\/EJE-09-0012","volume":"160","author":"E Delgrange","year":"2009","unstructured":"Delgrange E, Daems T, Verhelst J et al (2009) Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: A study in 122 patients. Eur J Endocrinol 160(5):747\u2013752. https:\/\/doi.org\/10.1530\/EJE-09-0012","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"1667_CR134","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1007\/s11102-020-01041-3","volume":"23","author":"L di Filippo","year":"2020","unstructured":"di Filippo L, Doga M, Resmini E et al (2020) Hyperprolactinemia and bone. Pituitary 23(3):314\u2013321. https:\/\/doi.org\/10.1007\/s11102-020-01041-3","journal-title":"Pituitary"},{"issue":"6","key":"1667_CR135","doi-asserted-by":"publisher","first-page":"E1216","DOI":"10.1152\/ajpendo.2000.279.6.E1216","volume":"279","author":"D Coss","year":"2000","unstructured":"Coss D, Yang L, Kuo CB et al (2000) Effects of prolactin on osteoblast alkaline phosphatase and bone formation in the developing rat. Am J Physiol Endocrinol Metab 279(6):E1216\u20131225. https:\/\/doi.org\/10.1152\/ajpendo.2000.279.6.E1216","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"1","key":"1667_CR136","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1210\/endo.140.1.6436","volume":"140","author":"P Cl\u00e9ment-Lacroix","year":"1999","unstructured":"Cl\u00e9ment-Lacroix P, Ormandy C, Lepescheux L et al (1999) Osteoblasts are a new target for prolactin: analysis of bone formation in prolactin receptor knockout mice. Endocrinology 140(1):96\u2013105. https:\/\/doi.org\/10.1210\/endo.140.1.6436","journal-title":"Endocrinology"},{"issue":"3","key":"1667_CR137","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.bone.2007.11.008","volume":"42","author":"D Seriwatanachai","year":"2008","unstructured":"Seriwatanachai D, Thongchote K, Charoenphandhu N et al (2008) Prolactin directly enhances bone turnover by raising osteoblast-expressed receptor activator of nuclear factor kappaB ligand\/osteoprotegerin ratio. Bone 42(3):535\u2013546. https:\/\/doi.org\/10.1016\/j.bone.2007.11.008","journal-title":"Bone"},{"issue":"6","key":"1667_CR138","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1080\/09513590.2018.1548592","volume":"35","author":"F Saki","year":"2019","unstructured":"Saki F, Sadeghian F, Kasaee SR et al (2019) The effect of prolactin itself and in combination with estrogen on bone mineral density in female rats. Gynecol Endocrinol 35(6):539\u2013543. https:\/\/doi.org\/10.1080\/09513590.2018.1548592","journal-title":"Gynecol Endocrinol"},{"issue":"10","key":"1667_CR139","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1038\/onc.2008.473","volume":"28","author":"L Gonz\u00e1lez","year":"2009","unstructured":"Gonz\u00e1lez L, Zambrano A, Lazaro-Trueba I et al (2009) Activation of the unliganded estrogen receptor by prolactin in breast cancer cells. Oncogene 28(10):1298\u20131308. https:\/\/doi.org\/10.1038\/onc.2008.473","journal-title":"Oncogene"},{"issue":"6","key":"1667_CR140","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1007\/s11102-024-01469-x","volume":"27","author":"MM Uygur","year":"2024","unstructured":"Uygur MM, Menotti S, Santoro S et al (2024) Modern approach to bone comorbidity in prolactinoma. Pituitary 27(6):802\u2013812. https:\/\/doi.org\/10.1007\/s11102-024-01469-x","journal-title":"Pituitary"},{"issue":"1\u20132","key":"1667_CR141","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s11010-010-0674-4","volume":"349","author":"K Wongdee","year":"2011","unstructured":"Wongdee K, Tulalamba W, Thongbunchoo J et al (2011) Prolactin alters the mRNA expression of osteoblast-derived osteoclastogenic factors in osteoblast-like UMR106 cells. Mol Cell Biochem 349(1\u20132):195\u2013204. https:\/\/doi.org\/10.1007\/s11010-010-0674-4","journal-title":"Mol Cell Biochem"},{"issue":"4","key":"1667_CR142","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1002\/jcb.22161","volume":"107","author":"D Seriwatanachai","year":"2009","unstructured":"Seriwatanachai D, Krishnamra N, van Leeuwen JP (2009) Evidence for direct effects of prolactin on human osteoblasts: Inhibition of cell growth and mineralization. J Cell Biochem 107(4):677\u2013685. https:\/\/doi.org\/10.1002\/jcb.22161","journal-title":"J Cell Biochem"},{"issue":"8","key":"1667_CR143","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.1210\/endo.139.8.6141","volume":"139","author":"Y Zhu","year":"1998","unstructured":"Zhu Y, Goff JP, Reinhardt TA et al (1998) Pregnancy and lactation increase vitamin D-dependent intestinal membrane calcium adenosine triphosphatase and calcium binding protein messenger ribonucleic acid expression. Endocrinology 139(8):3520\u20133524. https:\/\/doi.org\/10.1210\/endo.139.8.6141","journal-title":"Endocrinology"},{"issue":"10","key":"1667_CR144","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1139\/y00-040","volume":"78","author":"P Piyabhan","year":"2000","unstructured":"Piyabhan P, Krishnamra N, Limlomwongse L (2000) Changes in the regulation of calcium metabolism and bone calcium content during growth in the absence of endogenous prolactin and during hyperprolactinemia: A longitudinal study in male and female Wistar rats. Can J Physiol Pharmacol 78(10):757\u2013765. https:\/\/doi.org\/10.1139\/y00-040","journal-title":"Can J Physiol Pharmacol"},{"issue":"1","key":"1667_CR145","doi-asserted-by":"publisher","first-page":"R95","DOI":"10.1530\/JME-13-0220","volume":"52","author":"ND Horseman","year":"2013","unstructured":"Horseman ND, Gregerson KA (2013) Prolactin actions. J Mol Endocrinol 52(1):R95\u2013R106. https:\/\/doi.org\/10.1530\/JME-13-0220","journal-title":"J Mol Endocrinol"},{"issue":"1","key":"1667_CR146","doi-asserted-by":"publisher","first-page":"101453","DOI":"10.1016\/j.jocd.2023.101453","volume":"27","author":"L Nagendra","year":"2024","unstructured":"Nagendra L, Dutta D, Mondal S et al (2024) Hyperprolactinemia due to prolactinoma has an adverse impact on bone health with predominant impact on trabecular bone: A systematic review and meta-analysis. J Clin Densitom 27(1):101453. https:\/\/doi.org\/10.1016\/j.jocd.2023.101453","journal-title":"J Clin Densitom"},{"issue":"3","key":"1667_CR147","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.3390\/ijms25031474","volume":"25","author":"SJ Yun","year":"2024","unstructured":"Yun SJ, Sang H, Park SY et al (2024) Effect of hyperprolactinemia on bone metabolism: Focusing on osteopenia\/osteoporosis. Int J Mol Sci 25(3):1474. https:\/\/doi.org\/10.3390\/ijms25031474","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1667_CR148","doi-asserted-by":"publisher","first-page":"5122","DOI":"10.1038\/s41598-021-84606-x","volume":"11","author":"L Andereggen","year":"2021","unstructured":"Andereggen L, Frey J, Andres RH (2021) Persistent bone impairment despite long-term control of hyperprolactinemia and hypogonadism in men and women with prolactinomas. Sci Rep 11(1):5122. https:\/\/doi.org\/10.1038\/s41598-021-84606-x","journal-title":"Sci Rep"},{"issue":"4","key":"1667_CR149","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s11102-011-0293-4","volume":"14","author":"G Mazziotti","year":"2011","unstructured":"Mazziotti G, Mancini T, Mormando M (2011) High prevalence of radiological vertebral fractures in women with prolactin-secreting pituitary adenomas. Pituitary 14(4):299\u2013306. https:\/\/doi.org\/10.1007\/s11102-011-0293-4","journal-title":"Pituitary"},{"issue":"3","key":"1667_CR150","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1007\/s12020-011-9462-5","volume":"39","author":"G Mazziotti","year":"2011","unstructured":"Mazziotti G, Porcelli T, Mormando M et al (2011) Vertebral fractures in males with prolactinoma. Endocrine 39(3):288\u2013293. https:\/\/doi.org\/10.1007\/s12020-011-9462-5","journal-title":"Endocrine"},{"issue":"4","key":"1667_CR151","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s11154-021-09693-7","volume":"22","author":"JP Bilezikian","year":"2021","unstructured":"Bilezikian JP, Formenti AM, Adler RA, Vitamin D (2021) Dosing, levels, form, and route of administration: Does one approach fit all? Rev Endocr Metab Disord 22(4):1201\u20131218. https:\/\/doi.org\/10.1007\/s11154-021-09693-7","journal-title":"Rev Endocr Metab Disord"},{"issue":"5","key":"1667_CR152","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1210\/jc.2019-00221","volume":"104","author":"R Eastell","year":"2019","unstructured":"Eastell R, Rosen CJ, Black DM et al (2019) Pharmacological management of osteoporosis in postmenopausal women: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 104(5):1595\u20131622. https:\/\/doi.org\/10.1210\/jc.2019-00221","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1667_CR153","doi-asserted-by":"publisher","first-page":"210","DOI":"10.5603\/EP.2014.0029","volume":"65","author":"S Cander","year":"2014","unstructured":"Cander S, G\u00fcl \u00d6\u00d6, Ert\u00fcrk E et al (2014) Prolactin levels and gender are associated with tumour behaviour in prolactinomas but Ki-67 index is not. Endokrynol Pol 65(3):210\u2013216. https:\/\/doi.org\/10.5603\/EP.2014.0029","journal-title":"Endokrynol Pol"},{"issue":"1","key":"1667_CR154","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1210\/clinem\/dgaa756","volume":"106","author":"E Tsourdi","year":"2021","unstructured":"Tsourdi E, Zillikens MC, Meier C (2021) Fracture risk and management of discontinuation of denosumab therapy: A systematic review and position statement by ECTS. J Clin Endocrinol Metab 106(1):264\u2013281. https:\/\/doi.org\/10.1210\/clinem\/dgaa756","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"1667_CR155","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/s41574-023-00886-5","volume":"19","author":"S Petersenn","year":"2023","unstructured":"Petersenn S, Fleseriu M, Casanueva FF (2023) Diagnosis and management of prolactin-secreting pituitary adenomas: A Pituitary Society international consensus statement. Nat Rev Endocrinol 19(12):722\u2013740. https:\/\/doi.org\/10.1038\/s41574-023-00886-5","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"1667_CR156","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/s41584-024-01094-9","volume":"20","author":"NR Fuggle","year":"2024","unstructured":"Fuggle NR, Beaudart C, Bruy\u00e8re O (2024) Evidence-based guideline for the management of osteoporosis in men. Nat Rev Rheumatol 20(4):241\u2013251. https:\/\/doi.org\/10.1038\/s41584-024-01094-9","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"1667_CR157","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1210\/jcem-72-2-477","volume":"72","author":"A Beckers","year":"1991","unstructured":"Beckers A, Stevens C, Mahler C (1991) Thyrotropin-secreting pituitary adenomas: Report of seven cases. J Clin Endocrinol Metab 72(2):477\u2013483. https:\/\/doi.org\/10.1210\/jcem-72-2-477","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1667_CR158","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1007\/s11102-024-01467-z","volume":"27","author":"M Losa","year":"2024","unstructured":"Losa M, Vassallo A, Frara S et al (2024) TSH-secreting pituitary adenomas and bone. Pituitary 27(6):752\u2013760. https:\/\/doi.org\/10.1007\/s11102-024-01467-z","journal-title":"Pituitary"},{"issue":"1","key":"1667_CR159","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s40618-017-0753-4","volume":"41","author":"GR Williams","year":"2018","unstructured":"Williams GR, Bassett JHD (2018) Thyroid diseases and bone health. J Endocrinol Invest 41(1):99\u2013109. https:\/\/doi.org\/10.1007\/s40618-017-0753-4","journal-title":"J Endocrinol Invest"},{"issue":"8","key":"1667_CR160","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1001\/archinte.1982.00340210142025","volume":"142","author":"G Dickstein","year":"1982","unstructured":"Dickstein G, Barzilai D (1982) Hypothyroidism Secondary to Biologically Inactive Thyroid-Stimulating Hormone Secretion by a Pituitary Chromophobe Adenoma: Recovery After Removal of the Tumor. Arch Intern Med 142(8):1544\u20131545. https:\/\/doi.org\/10.1001\/archinte.1982.00340210142025","journal-title":"Arch Intern Med"},{"issue":"9","key":"1667_CR161","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/0026-0495(92)90129-X","volume":"41","author":"J Magner","year":"1992","unstructured":"Magner J, Klibanski A, Fein H et al (1992) Ricin and lentil lectin-affinity chromatography reveals oligosaccharide heterogeneity of thyrotropin secreted by 12 human pituitary tumors. Metabolism 41(9):1009\u20131015. https:\/\/doi.org\/10.1016\/0026-0495(92)90129-X","journal-title":"Metabolism"},{"issue":"9","key":"1667_CR162","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1210\/js.2018-00091","volume":"2","author":"S Frara","year":"2018","unstructured":"Frara S, Losa M, Doga M et al (2018) High prevalence of radiological vertebral fractures in patients with TSH-secreting pituitary adenoma. J Endocr Soc 2(9):1089\u20131099. https:\/\/doi.org\/10.1210\/js.2018-00091","journal-title":"J Endocr Soc"},{"issue":"2","key":"1667_CR163","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1515\/hmbci-2016-0015","volume":"28","author":"M Zaidi","year":"2016","unstructured":"Zaidi M, Kim SM, Ryu V et al (2026) Neuroendocrine and neural control of bone mass in health and disease. J Clin Invest 136(9):e203623. https:\/\/doi.org\/10.1172\/JCI203623","journal-title":"Horm Mol Biol Clin Investig"},{"key":"1667_CR164","doi-asserted-by":"publisher","first-page":"149442","DOI":"10.1016\/j.gene.2025.149442","volume":"955","author":"W Zhang","year":"2025","unstructured":"Zhang W, Chen Y, Wang Y et al (2025) TSH inhibits osteoclast differentiation through AMPK signaling pathway. Gene 955:149442. https:\/\/doi.org\/10.1016\/j.gene.2025.149442","journal-title":"Gene"},{"issue":"1","key":"1667_CR165","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13293-016-0089-3","volume":"7","author":"H Rakov","year":"2016","unstructured":"Rakov H, Engels K, H\u00f6nes GS et al (2016) Sex-specific phenotypes of hyperthyroidism and hypothyroidism in mice. Biol Sex Differ 7(1):36. https:\/\/doi.org\/10.1186\/s13293-016-0089-3","journal-title":"Biol Sex Differ"},{"issue":"3","key":"1667_CR166","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1210\/en.2018-00998","volume":"160","author":"E Tsourdi","year":"2019","unstructured":"Tsourdi E, Colditz J, Lademann F et al (2019) The Role of Dickkopf-1 in Thyroid Hormone-Induced Changes of Bone Remodeling in Male Mice. Endocrinology 160(3):664\u2013674. https:\/\/doi.org\/10.1210\/en.2018-00998","journal-title":"Endocrinology"},{"key":"1667_CR167","doi-asserted-by":"publisher","unstructured":"Liu J, Li Y, Liu J (2025) Impairment of Bone Mineral Density in Pituitary Thyrotropin-Secreting Adenomas: A Retrospective, Controlled Study. Endocr Pract 30:S1530-891X(25)01227-3. https:\/\/doi.org\/10.1016\/j.eprac.2025.09.202","DOI":"10.1016\/j.eprac.2025.09.202"},{"issue":"5","key":"1667_CR168","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s11102-023-01345-0","volume":"26","author":"A Giustina","year":"2023","unstructured":"Giustina A, Uygur MM, Frara S et al (2023) Pilot study to define criteria for Pituitary Tumors Centers of Excellence (PTCOE): results of an audit of leading international centers. Pituitary 26(5):583\u2013596. https:\/\/doi.org\/10.1007\/s11102-023-01345-0","journal-title":"Pituitary"},{"issue":"3","key":"1667_CR169","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.ecl.2020.05.010","volume":"49","author":"S Frara","year":"2020","unstructured":"Frara S, Rodriguez-Carnero G, Formenti AM et al (2020) Pituitary Tumors Centers of Excellence. Endocrinol Metab Clin North Am 49(3):553\u2013564. https:\/\/doi.org\/10.1016\/j.ecl.2020.05.010","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"4","key":"1667_CR170","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s11102-024-01397-w","volume":"27","author":"A Giustina","year":"2024","unstructured":"Giustina A, Uygur MM, Frara S et al (2024) Standards of care for medical management of acromegaly in pituitary tumor centers of excellence (PTCOE). Pituitary 27(4):381\u2013388. https:\/\/doi.org\/10.1007\/s11102-024-01397-w","journal-title":"Pituitary"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-026-01667-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-026-01667-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-026-01667-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T17:49:11Z","timestamp":1782409751000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-026-01667-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":170,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1667"],"URL":"https:\/\/doi.org\/10.1007\/s11102-026-01667-9","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"24 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A.G. has occasionaly consulted for Abiogen, Alexion, Amolyt Pharma, Crinetics, Ipsen, Pfizer and Recordati Rare Diseases, and received research grants to the Istitution by Recordati Rare Diseases. L.D.F. received research grants from Abiogen, and his research activities are partly supported by Glucocorticoid Induced Osteoporosis Skeletal Endocrinology Group (GIOSEG). A.G. is Editor in Chief of Pituitary. L.D.F is Associate Editor of Pituitary. All other authors have no conflict of interest to declare. The work submitted for publication is original and has not been published in any language or format, and has not been submitted elsewhere for print or electronic publication consideration.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"96"}}